

Massimo Dal Monte

Curriculum Vitae et Studiorum

Date of birth: November 6, 1964 (Pontedera, Pisa, Italy).

Position: Full Professor of Physiology, Department of Biology, University of Pisa, Italy.

Contacts: Prof. Massimo Dal Monte, Department of Biology, University of Pisa, via San Zeno, 31, 56127 Pisa (Italy). Telephone: +390502211426. Email: massimo.dalmonete@unipi.it.

Education and career

June 2018-present: Full Professor of Physiology, Department of Biology, University of Pisa, Italy.

2014-2018: Associate Professor of Physiology, Department of Biology, University of Pisa, Italy.

June 2009-November 2009: Visiting Fellow, Department of Molecular Genetics, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.

2006-2014: Researcher of Physiology, Department of Biology, University of Pisa, Italy.

2002-2005: Postdoc fellow, Department of Physiology and Biochemistry, University of Pisa, Italy.

2001-2002: Technician (D category), Department of Physiology and Biochemistry, University of Pisa, Italy.

1998: Specialization in Biochemistry and Clinical Chemistry, University of Pisa, Italy (magna cum laude)

1996-2000: Postdoc fellow, Department of Physiology and Biochemistry, University of Pisa, Italy.

1996: PhD in Biochemistry, University of Florence, Italy.

1992-1996: PhD student, Department of Physiology and Biochemistry, University of Pisa, Italy.

1990-1992: Fellow, Institute of Mutagenesis and Differentiation, CNR, Pisa, Italy.

1990: Master degree in Biology, University of Pisa, Italy (magna cum laude).

Institutional and organizational activities

October 2019-present: vice-president of the Bachelor degree in Biotechnology, Department of Biology, University of Pisa, Italy.

October 2019-present: vice-president of the Master degree in Molecular Biotechnology, Department of Biology, University of Pisa, Italy.

2018-present: Member of the Scientific Committee of Area 05 – Biology, University of Pisa, Italy.

2015-present: Coordinator of International Collaborations, Department of Biology, University of Pisa, Italy.

2015-present: Erasmus+ Coordinator, Department of Biology, University of Pisa, Italy.

2015-present: Chair of the General Physiology Unit, Department of Biology, University of Pisa, Italy.

2014-2019: Member of the Animal Welfare Board, University of Pisa, Italy.

2012-present: Member of the Board of the Ph.D. program in Molecular Medicine, University of Siena, Italy.

2012-present: Member of the Departmental Council, Department of Biology, University of Pisa, Italy.

2012-2019: Responsible of the Animal Facility, Department of Biology, University of Pisa, Italy.

2012-2018: Member of the Scientific Committee of the Library of Natural and Environmental Sciences, Chemistry, Mathematics, Informatics and Physics, University of Pisa, Italy.

2012-2016: Member of the Scientific Committee of Area 05 – Biology, University of Pisa, Italy.

2009-2011: Member of the Board of the Ph.D. School in Biological and Molecular Sciences, University of Pisa, Italy.

2009-2011: Member of the Board of the Ph.D. School in Neurosciences and Endocrine-metabolic Sciences, University of Pisa, Italy.

2008-2010: Member of the Scientific Committee of Area 05 – Biology, University of Pisa, Italy.

2008-2012: Member of the Scientific Committee of the Library of Natural and Environmental Sciences, University of Pisa, Italy.

2007-2010: Member of the Board of Dean's Advisor, Faculty of Sciences, University of Pisa, Italy.

2010: Supporting activities in the organization of the commemoration of the centennial anniversary of Moruzzi's birthday.

2009-2011: Member of the Board of the Ph.D. School in Basic and Developmental Neurosciences, University of Pisa, Italy.

2009-2012: Supporting activities in the organization of the Annual Meeting of Young Researchers in Physiology in Pisa (2009 and 2010) and in Sestri Levante (2011 and 2012).

2006-2008: Member of the Scientific Committee of Area 05 – Biology, University of Pisa, Italy.

2004: Supporting activities in the organization of the 55th National Congress of the Physiological Society of Italy

Teaching activities

Bachelor degree in Biotechnology, Department of Biology, University of Pisa, Italy: Cell and Systems Physiology.

Bachelor degree in Natural Sciences, Department of Biology, University of Pisa, Italy: General Physiology.

Master degree in Molecular Biotechnology, Department of Biology, University of Pisa, Italy: Advanced Neurosciences; Biotechnology in Neurosciences.

Master degree in Marine Biology, Zhejiang Ocean University, Zhoushan, Dinghai, China: Physiology of Marine Animals.

Research activities

Role of neuropeptides in retinal physiology

Molecular mechanisms underlying retinopathy of prematurity

Functional role of the beta adrenergic system: retinopathy of prematurity, retinitis pigmentosa and melanoma

Functional role of beta-3 adrenoceptors as oxygen sensors

Molecular mechanisms underlying diabetic retinopathy

Functional role of the uPAR system in diabetic retinopathy

Molecular mechanisms underlying retinitis pigmentosa

Role of neuroinflammation in retinal diseases

Nutraceuticals in the treatment of retinal diseases

Eye drops based on natural products to treat eye diseases

Editorial activities

2020-present: Biomolecules, Editorial Board Member.

2018-present: Frontiers in Bioengineering and Biotechnology, Review Editor.

2018-present: Frontiers in Molecular Biosciences, Review Editor.

2018-present: Frontiers in Pediatrics, Review Editor.

Ad-hoc reviewer for more than 50 journals including: Acta Ophthalmologica; American Journal of Pathology; Angiogenesis; British Journal of Pharmacology; Diabetes, Obesity and Metabolism; Experimental Eye Research; Investigative Ophthalmology & Visual Science; Journal of Neurochemistry; Journal of Ophthalmology; Journal of Pathology; Molecular Vision; Nutrients.

Ad hoc reviewer for granting agencies

MIUR

French Ministry of Health

National Cancer Institute of France

National Science Center Poland.

Affiliation to Scientific Societies

Italian Physiological Society (SIF)

European Association for Vision and Eye Research (EVER)

European Association for the Study of Diabetes (EASD)

Research Grants

2020: Research grant from Azienda Ospedaliero-Universitaria Meyer, Italy.

2020: Research grant from Sooft Italia SpA, Italy.

2018-present: Research grant from the University of Pisa, Italy.

2018-2019: Research grant from Sooft Italia SpA, Italy.

2016-2017: Research grant from Indena SpA, Italy.

2015-2016: Research grant from the University of Pisa, Italy.

2013-2014: Research grant from Ospedale Pediatrico Meyer, Italy.

2011-2013: Research grant from The International Retina Research Foundation, USA.

2011-2012: Research grant from Fondazione Meyer, Italy.

2009-2011: Research grant from The International Retina Research Foundation, USA.

2008-2010: Research grant from the University of Pisa, Italy.

2007-2008: Research grant from Fondazione Cassa di Risparmio di Volterra, Italy.

2006-present: Annual support from the University of Pisa, Italy.

Invited talks

2018: Beta3-adrenoceptors as drug targets in melanoma. 10th Adrenoceptor Symposium. Shizuoka; Japan; June 28th-30th.

2017 Anti-angiogenic and anti-inflammatory role of boswellic acids. Workshop "Progetto IDARA - Alimenti funzionali: un valido ausilio nel controllo della patologia diabetica e dei processi infiammatori". Pisa; June 22nd.

2017: Effect of Macular FAG in a murine model of macular degeneration. Third International Congress Vitreo-Retina Forever; Acquaviva delle Fonti (BA); January 12th-14th.

2016: The beta-adrenergic system as a possible new target for pharmacological treatment of neovascular retinal diseases. Symposium "Old drugs-new uses: novel therapies targeting the beta adrenergic system". Sixty-seventh Annual Meeting of the Physiological Society of Italy; Catania; September 21st-23rd.

2015: Treating proliferative retinopathies: from laser photocoagulation to anti-VEGF drugs and beyond. SIICA Workshop "Angiogenesi: basi molecolari ed implicazioni terapeutiche V"; Certosa di Pontignano (SI); May 25th-27th.

2013: Role of beta adrenergic system in retinal angiogenesis. SIICA Workshop "Angiogenesi: basi molecolari ed implicazioni terapeutiche IV"; Certosa di Pontignano (SI); May 13rd-15th.

2012: Neuroprotective factors against retinal injury in response to hypoxia: new perspectives. Symposium "Neuronal death processes in retinal disease"; European Association for Vision and Eye Research Congress 2012; Nice, France; October 10th-13th.

2010: Retinal neovascularisation and its implication in retinal dysfunctions. Symposium "Cerebral blood flow and neuronal functions: from physiology to animal models of vascular pathology"; Sixty-first Annual Meeting of the Physiological Society of Italy; Varese; September 15th-17th.

Publications of the last 5 years

1. Locri F.; Pesce N.A.; Aronsson M.; Cammalleri M.; De Rosa M.; Pavone V.; Bagnoli P.; Kvanta A.; **Dal Monte M.**; André H. (2020). “Gaining insight on mitigation of rubeosis iridis by UPARANT in a mouse model associated with proliferative retinopathy”. *J. Mol. Med.*, *submitted*.
2. Filippi L.; **Dal Monte M.** (2020). “A safety review of drugs used for the treatment of retinopathy of prematurity”. *Expert Opin. Drug Saf.*, *submitted*.
3. **Dal Monte M.**; Cammalleri M.; Amato R.; Pezzino S.; Corsaro R.; Bagnoli P.; Rusciano D. (2020). “Melatonergic compounds counteract retinal ganglion cell loss and prevent visual dysfunction in rats with experimental glaucoma”. *Invest. Ophthalmol. Vis. Sci.*, *submitted*.
4. Rossino M.G.; Lulli M.; Amato R.; Cammalleri M.; **Dal Monte M.**; Casini G. (2020). “Oxidative stress induces a VEGF autocrine loop in the retina: relevance for diabetic retinopathy”. *Cells*, 9:1452.
5. Cammalleri M.; **Dal Monte M.**; Amato R.; Bagnoli P.; Rusciano D. (2020). “A dietary combination of forskolin with homotaurine, spearmint and B vitamins protects injured retinal ganglion cells in a rodent model of hypertensive glaucoma”. *Nutrients*, 12:1189.
6. **Dal Monte M.**; Cammalleri M.; Pezzino S.; Corsaro R.; Pescosolido N.; Bagnoli P.; Rusciano D. (2020). “Hypotensive Effect of Nanomicellar Formulation of Melatonin and Agomelatine in a Rat Model: Significance for Glaucoma Therapy”. *Diagnostics (Basel)*, 10: E138.
7. **Dal Monte M.**; Tavanti A.; Poma N.; Rusciano D. (2020). “Dexamethasone Improves Ofloxacin Efficacy in Treating Acute Bacterial Conjunctivitis: Evidence from A Rabbit Model.” *Biomed. J. Sci.Tech. Res.* 26: 19598-19605.
8. Amato R.; Giannaccini M.; **Dal Monte M.**; Cammalleri M.; Pini A.; Raffa V.; Lulli M.; Casini G. (2020). “Association of the somatostatin analog octreotide with magnetic nanoparticles for intraocular delivery: a possible approach for the treatment of diabetic retinopathy”. *Front. Bioeng. Biotechnol.*, 8: 144.
9. **Dal Monte M.**; Evans B.; Arioglu-Inan E.; Michel M.C. (2020). “Upregulation of β_3 -adrenergic receptors – a general marker of and protective mechanism against hypoxia?”. *Naunyn Schmiedebergs Arch. Pharmacol.*, 393: 141-146.
10. Locri F.; Cammalleri M.; **Dal Monte M.**; Rusciano D.; Bagnoli P. (2019). “Protective efficacy of a dietary supplement based on forskolin, homotaurine, spearmint extract and group B vitamins in a mouse model of optic nerve injury”. *Nutrients*, 11:2931.
11. Filippi L.; Cavallaro G.; Perciasepe L.; Sandini E.; Araimo G.; Regiroli G.; Raffaelli G.; Bagnoli P.; **Dal Monte M.**; Calvani M.; Fortunato P.; Osnaghi S.; Mosca F. (2019). “Refractive outcome in preterm newborns with ROP after propranolol treatment. A retrospective observational cohort study”. *Front. Pediatr.*, 7:479.
12. Rossino M.G.; **Dal Monte M.**; Casini G. (2019). “Relationships between neurodegeneration and vascular damage in diabetic retinopathy”. *Front. Neurosci.*, 13:1172.
13. Locri F.; **Dal Monte M.**; Aronsson M.; Cammalleri M.; De Rosa M.; Pavone V.; Kvanta A.; Bagnoli P.; André H. (2019). “UPARANT is an effective antiangiogenic agent in a mouse model of rubeosis iridis”. *J. Mol. Med.*;23:5176-5192.
14. ; Cammalleri M.; **Dal Monte M.**; Pavone V.; De Rosa M.; Rusciano D.; Bagnoli P. (2019). “The uPAR system as a potential therapeutic target in the diseased eye”. *Cells*; 8:925.
15. Cammalleri M.; **Dal Monte M.**; Locri F.; Pecci V.; De Rosa M.; Pavone V.; Bagnoli P. (2019). “The urokinase-type plasminogen activator system as drug target in retinitis pigmentosa: new preclinical evidence in the rd10 mouse model”. *J. Cell. Mol. Med.* 23:5176-5192.
16. Calvani M.; Bruno G.; **Dal Monte M.**; Nassini R.; Fontani F.; Casini A.; Cavallini L.; Becatti M.; Bianchini F.; De Logu F.; Forni G.; la Marca G.; Calorini L.; Bagnoli P.; Chiarugi P.; Pupi A.; Azzari C.; Geppetti P.; Favre C.; Filippi L. (2019). “ β_3 -adrenoceptor as a potential immunosuppressor agent in melanoma”. *Br. J. Pharmacol.*; 176:2509-2524.

17. **Dal Monte M.**; Calvani M.; Cammalleri M.; Favre C.; Filippi L.; Bagnoli P. (2019). “ β -adrenoceptors as drug targets in melanoma: novel preclinical evidence for a role of β 3-adrenoceptors”. *Br. J. Pharmacol.*; 176:2496-2508.
18. Filippi L.; Cavallaro G.; Berti E.; Padrini L.; Araimo G.; Regiroli G.; Raffaelli G.; Bozzetti V.; Tagliabue P.; Tomasini B.; Mori A.; Buonocore G.; Agosti M.; Bossi A.; Chirico G.; Aversa S.; Fortunato P.; Osnaghi S.; Cavallotti B.; Susani M.; Vanni M.; Borsari G.; Donati S.; Nascimbeni G.; Nardo D.; Piermarocchi S.; la Marca G.; Forni G.; Milani S.; Cortinovis I.; Calvani M.; Bagnoli P.; **Dal Monte M.**; Calvani A.M.; Pugi A.; Villamor E.; Donzelli G.; Mosca F. (2019). “Propranolol 0.2% eye micro-drops for Retinopathy of Prematurity: a prospective phase IIB study”. *Front. Pediatr.*; 7:180.
19. **Dal Monte M.**; Cammalleri M.; Pecci V.; Carmosino M.; Procino G.; De Rosa M.; Pavone V.; Svelto M.; Bagnoli P. (2019). “Inhibiting the urokinase-type plasminogen activator receptor system recovers STZ-induced diabetic nephropathy”. *J. Cell. Mol. Med.*; 23:1034-1049.
20. Amato R.; Rossino M.G.; Cammalleri M.; Locri F.; Pucci L.; **Dal Monte M.**; Casini G. (2018). “Lisosan G Protects the Retina from Neurovascular Damage in Experimental Diabetic Retinopathy”. *Nutrients*; 10:1932.
21. Calvani M.; Cavallini L.; Tondo A.; Spinelli V.; Ricci L.; Pasha A.; Bruno G.; Buonvicino D.; Bigagli E.; Vignoli M.; Bianchini F.; Sartiani L.; Lodovici M.; Semeraro R.; Fontani F.; De Logu F.; **Dal Monte M.**; Chiarugi P.; Favre C.; Filippi L. (2018). “ β 3-adrenoreceptors control mitochondrial dormancy in melanoma and embryonic stem cells”. *Oxid. Med. Cell. Longev.*; 2018:6816508.
22. Locri F.; Cammalleri M.; Pini A.; **Dal Monte M.**; Rusciano D.; Bagnoli P. (2018). “Further evidence on efficacy of diet supplementation with fatty acids in ocular pathologies: insights from the EAE model of optic neuritis”. *Nutrients*; 10:1447.
23. Amato R.; **Dal Monte M.**; Lulli M.; Raffa V.; Casini G. (2018). “Nanoparticle-Mediated Delivery of Neuroprotective Substances for the Treatment of Diabetic Retinopathy”. *Curr. Neuropharmacol.*; 16:993-1003.
24. **Dal Monte M.**; Cammalleri M.; Locri F.; Amato R.; Marsili S.; Rusciano D.; Bagnoli P. (2018). “Fatty acids dietary supplement exerts anti-inflammatory action and limits ganglion cell degeneration in the retina of the EAE mouse model of multiple sclerosis”. *Nutrients*; 10:325.
25. Amato R.; Catalani E.; **Dal Monte M.**; Cammalleri M.; Di Renzo I.; Perrotta C.; Cervia D.; Casini G. (2018). “Autophagy-mediated neuroprotection induced by octreotide in an ex vivo model of early diabetic retinopathy”. *Pharmacol. Res.*; 128:167-178.
26. Pisani F.; Cammalleri M.; **Dal Monte M.**; Locri F.; Mola M.G.; Nicchia G.P.; Frigeri A.; Bagnoli P.; Svelto M. (2018). “Limited accessibility of HIF-1 to the *VEGF* gene promoter reduces retinal VEGF transcription and ameliorates oxygen induced retinopathy in AQP4 KO mice”. *J. Cell. Mol. Med.*; 22:613-627.
27. Cammalleri M.; **Dal Monte M.**; Locri F.; Marsili S.; Lista L.; De Rosa M.; Pavone V.; Rusciano D.; Bagnoli P. (2017). “Diabetic Retinopathy in the Spontaneously Diabetic Torii Rat: Pathogenetic Mechanisms and Preventive Efficacy of Inhibiting the Urokinase-Type Plasminogen Activator Receptor System”. *J. Diabetes Res.*; 2017:2904150.
28. Cammalleri M.; Locri F.; Catalani E.; Filippi L.; Cervia D.; **Dal Monte M.**; Bagnoli P. (2017). “The Beta Adrenergic Receptor Blocker Propranolol Counteracts Retinal Dysfunction in a Mouse Model of Oxygen Induced Retinopathy: Restoring the Balance Between Apoptosis and Autophagy”. *Front. Cell. Neurosci.*; 11:395.
29. Cammalleri M.; **Dal Monte M.**; Locri F.; Lardner E.; Kvanta A.; Rusciano D.; André H.; Bagnoli P. (2017). “Efficacy of fatty acids dietary supplement in polyethylene glycol-induced mouse model of retinal degeneration”. *Nutrients*; 9:1079.
30. Barontini J.; Antinucci M.; Tofanelli S.; Cammalleri M.; **Dal Monte M.**; Gemignani F.; Vodicka P.; Marangoni R.; Vodickova L.; Kupcinskas J.; Vymetalkova V.; Forsti A.; Canzian F.; Stein A.; Moreno V.; Mastrodonato N.; Tavano F.; Panza A.; Barale R.; Landi S.; Campa D.

- (2017). "Association between polymorphisms of *TAS2R16* and susceptibility to colorectal cancer". *BMC Gastroenterol.*; 17:104.
31. Lulli M.; Cammalleri M.; Granucci I.; Witort E.; Di Gesualdo F.; Loffredo R.; Lupia A.; Casini G.; **Dal Monte M.**; Capaccioli S. (2017). "In vitro and in vivo inhibition of proangiogenic retinal phenotype by an antisense oligonucleotide downregulating uPAR expression". *Biochem. Biophys. Res. Commu.*; 490:977-983.
 32. Filippi L.; Cavallaro G.; Berti E.; Padrini L.; Araimo G.; Regiroli G.; Bozzetti V.; Tagliabue P.; Tomasini B.; Buonocore G.; Agosti M.; Bossi A.; Chirico G.; Aversa S.; Pasqualetti R.; Fortunato P.; Osnaghi S.; Cavallotti B.; Vanni M.; Borsari G.; Donati S.; Nascimbeni G.; la Marca G.; Forni G.; Milani S.; Cortinovia I.; Bagnoli P.; **Dal Monte M.**; Calvani A.M.; Pugi A.; Donzelli G.; Mosca F. (2017). "Study protocol: Safety and efficacy of propranolol 0.2% eye drops in newborns with a precocious stage of retinopathy of prematurity (DROP-ROP-0.2%): a multicenter; open-label; single arm; phase II pilot trial". *BMC Pediatr.*; 17:165.
 33. Cammalleri M.; Locri F.; Marsili S.; **Dal Monte M.**; Pisano C.; Mancinelli A.; Lista L.; Rusciano D.; De Rosa M.; Pavone V.; Bagnoli P. (2017). "The Urokinase Receptor-Derived Peptide UPARANT Recovers Dysfunctional Electroretinogram and Blood-Retinal Barrier leakage in a Rat Model of Diabetes". *Invest. Ophthalmol. Vis. Sci.*; 58:3138-3148.
 34. Filippi L.; Cavallaro G.; Bagnoli P.; **Dal Monte M.**; Fiorini P.; Berti E.; Padrini L.; Donzelli G.; Araimo G.; Cristofori G.; Fumagalli M.; la Marca G.; Della Bona M.L.; Pasqualetti R.; Fortunato P.; Osnaghi S.; Tomasini B.; Vanni M.; Calvani A.M.; Milani S.; Cortinovia I.; Pugi A.; Agosti M.; Mosca F. (2017). "Propranolol 0.1% eye micro-drops in newborns with retinopathy of prematurity: a pilot clinical trial". *Pediatric Res.*; 81:307-314.
 35. Procino G.; Carosino M.; Milano S.; **Dal Monte M.**; Schena G.; Mastrodonato M.; Torretta S.; Gerbino A.; Bagnoli P.; Svelto M. (2016). "Beta-3 Adrenergic Receptor (β 3-AR) in the kidney: a new player in sympathetic regulation of renal function". *Kidney Int.*; 90:555-567.
 36. Amato R.; Biagioni M.; Cammalleri M.; **Dal Monte M.**; Casini G. (2016). "VEGF as a survival factor in ex vivo models of early diabetic retinopathy". *Invest. Ophthalmol. Vis. Sci.*; 57:3066-3076.
 37. Cammalleri M.; **Dal Monte M.**; Locri F.; Lista L.; Aronsson M.; Kvanta A.; Rusciano D.; De Rosa M.; Pavone V.; Andrè H.; Bagnoli P. (2016). "The uPAR system inhibitor UPARANT mitigates angiogenesis in a mouse model of laser-induced choroidal neovascularization". *Invest. Ophthalmol. Vis. Sci.* 57:2600-2611.
 38. Nicchia G.P.; Pisani F.; Simone L.; Cibelli A.; Mola M.G.; **Dal Monte M.**; Frigeri A.; Bagnoli P.; Svelto M. (2016). "Glio-vascular modifications caused by Aquaporin-4 deletion in the mouse retina". *Exp. Eye Res.*; 146:259-268.
 39. Hernandez C.; **Dal Monte M.**; Simò R.; Casini G. (2016). "Diabetic retinopathy: Neuroprotection as a therapeutic target". *J. Diabetes Res.* 2016:9508541.
 40. **Dal Monte M.**; Casini G. (2016). "Indirect blockade of VEGF: the potential for eye disease therapy". *Expert Rev. Ophthalmol.* 11:1-4.
 41. Sereni F.; **Dal Monte M.**; Filippi L.; Bagnoli P. (2015). "Role of host β 1- and β 2-adrenergic receptors in a murine model of B16 melanoma: functional involvement of β 3-adrenergic receptors". *Naunyn Schmiedebergs Arch Pharmacol.* 388:1317-1331.
 42. Marranci A.; Tuccoli A.; Mercoledì E.; Vitiello M.; Sarti S.; Lubrano S.; Valdes C.; Russo F.; **Dal Monte M.**; Pellegrini M.; Capobianco E.; Tsinoremas N.; Polisenio L. (2015). "Identification of BRAF 3'UTR isoforms in melanoma". *J. Invest. Dermatol.* 135:1694-1697.
 43. Lulli M.; Cammalleri M.; Fornaciari I.; Casini G.; **Dal Monte M.** (2015). "Acetyl-11-keto- β -boswellic acid reduces retinal angiogenesis in a mouse model of oxygen-induced retinopathy". *Exp Eye Res.* 135:67-80.
 44. **Dal Monte M.**; Rezzola S.; Cammalleri M.; Belleri M.; Locri F.; Morbidelli L.; Corsini M.; Paganini G.; Semeraro F.; Cancarini A.; Rusciano D.; Presta M.; Bagnoli P. (2015). "Anti-

angiogenic effectiveness of the urokinase receptor-derived peptide UPARANT in a model of oxygen induced retinopathy”. *Invest. Ophthalmol. Vis. Sci.* 56(4):2392-2407.

45. Rezzola S.; **Dal Monte M.**; Belleri M.; Bugatti A.; Chioldelli P.; Corsini M.; Cammalleri M.; Cancarini A.; Morbidelli L.; Oreste P.; Bagnoli P.; Semeraro F.; Presta M. (2015). “Therapeutic potential of anti-angiogenic multi-target *N;O*-sulfated *E. Coli* K5 polysaccharide in diabetic retinopathy”. *Diabetes* 64:2581-2592.
46. Filippi L.; **Dal Monte M.**; Casini G.; Daniotti M.; Sereni F.; Bagnoli P. (2015). “Infantile Hemangiomas; Retinopathy of Prematurity and Cancer: a Common Pathogenetic Role of the β -adrenergic System”. *Med. Res. Rev.* 35(3):619-52.
47. **Dal Monte M.**; Cammalleri M.; Mattei E.; Filippi L.; Bagnoli P. (2015). “Protective effects of beta1/2 adrenergic receptor deletion in a model of oxygen induced retinopathy”. *Invest. Ophthalmol. Vis. Sci.* 56:59-73.

Book chapters

1. **Dal Monte M.** (2019) “Capitolo 7 – Sistema nervoso: organizzazione anatomica”. *In* Taglietti V. (Ed.) “Fondamenti di Fisiologia generale e integrata”. pp. 164-188. EdiSES, Napoli.
2. **Dal Monte M.** (2019) “Capitolo 8 – Sistema nervoso: sistemi motorio, sensoriale, autonomo e funzioni nervose superiori” (with the exception of the part deidcated to the sensory system). *In* Taglietti V. (Ed.) “Fondamenti di Fisiologia generale e integrata”. pp. 189-204; 271-291. EdiSES, Napoli.
3. Filippi L; Cammalleri M; **Dal Monte M.** (2015) “Targeting the Beta-Adrenergic System to Treat retinopathy of Prematurity: A New Therapeutic Approach?”. *In* Aguilar E. (Ed) “Retinopathy of Prematurity (ROP). Classification; Risk Factors and Treatment”. pp 1-34. Nova Science Publisher; New York.
4. **Dal Monte M.** (2011) “Modelli animali di patologie oculari”. *In* Carella G.; Cerulli L.; Simonetti G. (Eds) “La via ottica dalle origini alla contemporaneità”. pp 413-423. Edizioni SOI.

Patents

1. Svelto M.; Procino G.; Carmosino M.; **Dal Monte M.**; Bagnoli P. (2014). “Agonisti selettivi dei recettori beta-adrenergici di tipo 3 (BAR3) e loro impiego”. MI2014A001676. International patent.
2. Filippi L.; Bilia A.R.; Isacchi B.; la Marca G.; Bagnoli P.; **Dal Monte M.**; Fiorini P.; Ristori C. (2014). “Sistemi oftalmici per il rilascio di farmaci al segmento posteriore dell'occhio per la somministrazione oculare di beta-2-bloccanti per l'uso nel trattamento di retinopatie proliferative”. FI2014A000061. National patent.
3. Capaccioli S.; Lulli M.; **Dal Monte M.** (2010). “Uso di oligonucleotidi antisenso per il trattamento di degenerazioni e neoplasie retiniche”. MI20101030. National patent.

Bibliometric indexes

Google Scholar (July 21, 2020)

Citations: 2558
h index: 30

Scopus (July 21, 2020)

Citations: 1709
h index: 25

WOS (July 21, 2020)

Citations: 1898
h index: 26